Involvement of D1 dopamine receptors in the cognitive effects of angiotensin IV and des-Phe6 angiotensin IV

Peptides

Volumn 25, Issue 7, 2004, Pages 1195-1203

  Braszko, Jan J ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Angiotensin IV; Anxiety; Des Phe6 Angiotensin IV; Dopamine D1 receptors; Learning and memory; Locomotor activity

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANGIOTENSIN II [3-8]; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; ANGIOTENSIN II; ANGIOTENSIN II, DES ASP(1) DES ARG(2) ILE(5); ANGIOTENSIN II, DES-ASP(1)-DES-ARG(2)-ILE(5)-; ANGIOTENSIN IV, DES PHE(6); ANGIOTENSIN IV, DES-PHE(6)-; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; COGNITION; CONTROLLED STUDY; EMOTION; LEARNING; LOCOMOTION; MALE; MAZE TEST; MEMORY; MENTAL TASK; NONHUMAN; OPEN FIELD BEHAVIOR; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; RECALL; RECOGNITION; ANIMAL; BRAIN; DRUG EFFECT; EXPLORATORY BEHAVIOR; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; WISTAR RAT;

RATTUS NORVEGICUS;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANGIOTENSIN II; ANIMALS; AVOIDANCE LEARNING; BRAIN; COGNITION; EXPLORATORY BEHAVIOR; MALE; MAZE LEARNING; MOTOR ACTIVITY; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D1; RECOGNITION (PSYCHOLOGY);

EID: 3042789985     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2004.04.014     Document Type: Article

References (64)

1. 1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434. Eur J Pharmacol. 343:1998;111-118
2. Acquas E., Carboni E., Leone P., Di Chiara G. SCH 23390 blocks drug-conditioned place-preference and place-aversion: anhedonia (lack of reward) or apathy (lack of motivation) after dopamine-receptor blockade. Psychopharmacology. 99:1989;151-155
3. Ader R., Weijnen J.A.W.M., Moleman P. Retention of a passive avoidance responses as a function of the intensity and duration of electric shock. Psychon Sci. 26:1972;125-129
4. Allen A.M., Møeller I., Jenkins T.A., Zhuo J., Aldred G.P., Chai S.Y., et al. Angiotensin receptors in the nervous system. Brain Res Bull. 47(1):1998;17-28
5. Beninger R.J., Hoffman D.C., Mazurski E.J. Receptor subtype-specific dopaminergic agents and conditioned behavior. Neurosci Biobehav Rev. 13:1989;113-122
6. 1 receptors are involved in the mediation of procognitive effects of angiotensin IV and angiotensin II(3-7). In: Proceedings of the Sixth International Congress of Polish Neuroscience Society. Acta Neurobiol Exp. 63(3):2003;275. [abstracts]
7. Braszko JJ, Holy ZZ, Kupryszewski G, Witczuk B. Effect of angiotensin II, its 2-8, 3-8, 4-8 fragments and saralasin on the level and turnover of dopamine in the striatum and olfactory tubercle of the rat. Asia Pac J Pharmacol 1991;6:243-7.
8. Braszko J.J., Kupryszewski G., Witczuk B., Wiœniewski K. Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and conditioned avoidance responses in rats. Neuroscience. 27:1988;777-783
9. Braszko J.J., Paslawski L., Karwowska-Polecka W., Holownia A. Trandolapril attenuates acquisition of conditioned avoidance in rats. Pol J Pharmacol. 52:2000;195-201
10. Braszko J.J., Wiśniewski K., Kupryszewski G., Witczuk B. Psychotropic effects of angiotensin II and III in rats: locomotor and exploratory vs. cognitive behaviour. Behav Brain Res. 25:1987;195-203
11. Braszko J.J., Wlasienko J., Koziolkiewicz W., Janecka A., Wiœniewski K. The 3-7 fragment of angiotensin II is probably responsible for its psychoactive properties. Brain Res. 542:1991;49-54
12. Braun A.R., Chase T.N. Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. Eur J Pharmacol. 131:1986;301-306
13. Brown D.C.h., Steward L.J., Ge J., Barnes N.M. Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br J Pharmacol. 118:1996;414-420
14. Brozoski T.J., Brown R.M., Rosvold H.E., Goldman P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science. 205:1979;929-932
15. Bushnell P.J., Levin E.D. Effects of dopaminergic drugs on working and reference memory in rats. Pharmacol Biochem Behav. 45:1993;765-776
16. 1 receptors facilitate transmitter release. Nature. 366:1993;344-347
17. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 345:2001;1667-1675
18. 1 sites. Neuroscience. 28(2):1989;263-273
19. Cruz C.J., Beckstead R.M. Nigrostriatal dopamine neurons are required to maintain basal levels of substance P in the rat substantia nigra. Neuroscience. 30(2):1989;331-338
20. 1-receptor antagonist, on the behavioural responsiveness to small and larger doses of apomorphine in rats. Neuropharmacology. 25(11):1986;1297-1300
21. 2 dopamine agonists on stereotyped locomotion in rats. Behav Brain Res. 45:1991;117-124
22. 1 receptor knockout mice. Eur J Pharmacol. 383:1999;95-106
23. Ennaceur A., Meliani K. A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs. nonspatial working memory. Behav Brain Res. 51:1992;83-92
24. 1 receptors. Eur J Neurosci. 18(7):2003;2025
25. Frcka G., Lader M. Psychotropic effects of repeated doses of enalapril. Br J Clin Pharmacol. 25:1988;67-73
26. 2 dpamine agonists produce opposing effects in place conditioning but not in conditioned taste aversion learning. Pharmacol Biochem Behav. 31:1988;1-8
27. Hojo Y., Ikeda U., Katsuki Y., Mizuno O., Fujikawa H., Shimada K. Inhibition of angiotensin converting enzyme cannot prevent increases in angiotensin II production in coronary circulation. Heart. 83(5):2000;574-576
28. Hyttel J. SCH 23390 - the first selective dopamine D-1 antagonist. Eur J Pharmacol. 91:1983;153-154
29. Jenkins T.A., Mendelsohn F.A.O., Chai S.Y. Angiotensin-converting enzyme modulated dopamine turnover in the striatum. J Neurochem. 68:1997;1304-1311
30. Kobayashi M., Ohno M., Shibata S., Yamamoto T., Watanabe S. Concurrent blockade of beta-adrenergic and muscarinic receptors suppresses synergistically long-term potentiation of population spikes in the rat hippocampal CA1 region. Brain Res. 777:1997;242-246
31. Kono T., Ikeda F., Taniguchi A., Imura H., Oseko F., Yoshioka M., et al. Responses of patients with Bartter's syndrome to angiotensin III and angiotensin II-(3-8)-hexapeptide. Acta Endocrinol. 109:1985;249-253
32. Lee J., Chai S.Y., Mendelsohn F.A.O., Morris M.J., Allen A.M. Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7. Neuropharmacology. 40:2001;618-623
33. Mansour A, Watson SJ, Dopamine receptor expression in the central nervous system. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995: p. 207-19.
34. Matsuyama S., Matsumoto A., Enomoto T., Nishizaki T. Activation of nicotinic acetylcholine receptors induces long-term potentiation in vivo in the intact mouse dentate gyrus. Eur J Neurosci. 12:2000;3741-3747
35. McGurk S.R., Levin E.D., Butcher L.L. Dopaminergic drugs reverse the impairment of radial-arm maze performance caused by lesions involving the cholinergic medial pathway. Neuroscience. 50(1):1992;129-135
36. Mendelsohn F.A.O., Jenkins T.A., Berkovic S.F. Effect of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res. 613:1993;221-229
37. 2 receptors in human basal ganglia. Brain Res. 843:1999;136-144
38. Møeller I., Allen A.M., Chai S.Y., Zhuo J., Mendelsohn F.A.O. Bioactive angiotensin peptides. J Hum Hypertens. 12:1998;289-293
39. 4 receptors in the Macaca fascicularis brain. Brain Res. 712:1996;307-324
40. Mueck A.O., Seeger H., Lippert T.H. Valsartan inhibits angiotensin II-stimulated proliferation of smooth muscle cells from human coronary artery. Int J Clin Pharmacol Ther. 37:1999;365-366
41. Ohno M., Yamamoto T., Watanabe S. Involvement of cholinergic mechanisms in impairment of working memory in rats following basolateral amygdaloid lesions. Neuropharmacology. 31(9):1992;915-922
42. Packard M.G., White N.M. Memory facilitation produced by dopamine agonists: role of receptor sybtype and mnemonic requirements. Pharmacol Biochem Behav. 33:1989;511-518
43. Pawlak R., Napiorkowska-Pawlak D., Takada Y., Urano T., Nagai N., Ihara H., et al. The differential effect of angiotensin II and angiotensin 1-7 on norepinephrine, epinephrine, and dopamine concentrations in rat hypothalamus: the involvement of angiotensin receptors. Brain Res Bull. 54(6):2001;689-694
44. 4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. Regul Peptides. 102:2001;147-156
45. Pellow S., Chopin P., Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 14:1985;149-167
46. Reardon K.A., Mendelsohn F.A.O., Chai S.Y., Horne M.K. The effect of the angiotensin converting enzyme, perindopril, on clinical features of Parkinsons disease. Aust. N. Z. J. Med. 30(1):2000;48-53
47. Robertson MJ, Angiotensin antagonists. In: Leff P, editor. Receptor-based drug design. New York: Marcel Dekker Inc.; 1998. p. 207-29.
48. Rossi N.F. Dopaminergic control af angiotensin II-induced vasopressin secretion in vitro. Am J Physiol. 275:1998;E687-E693
49. Santos R.A.S., Campagnole-Santos M.J., Andrade S.P. Angiotensin (1-7): an update. Regul Peptides. 91:2000;45-62
50. 4 receptor binding characteristics: D-amino acid- and glycine-substituted peptides. Peptides. 14:1993;949-954
51. 1 dopamine receptors in prefrontal cortex: involvement in working memory. Science. 251:1991;947-950
52. Strange P.G. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev. 53:2001;119-133
53. Swanson G.N., Hanesworth J.M., Sardinia M.F., Coleman J.K.M., Miller-Wing A.V., Cook V.I., et al. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Peptides. 40:1992;409-419
54. Tarazi F.I. Neuropharmacology of dopamine receptors: implications in neuropsychiatric diseases. Med Sci. 3(2):2001;93-104
55. Wahlbeck K., Ahokas A., Nikkila H., Miettinen K., Rimón R. Cerebrospinal fluid angiotensin-converting enzyme (ACE) correlates with length of illness in schizophrenia. Schizophr Res. 41:2000;335-340
56. Warburton D.M., Rusted J.M. Cholinergic control of cognitive resources. Neuropsychobiology. 28:1993;43-46
57. Wayner M.J., Armstrong D.L., Phelix C.F., Harding J.W., Wright J.W. Angiotensin IV enhances LTP in rat dentate gyrus in vivo. Peptides. 22:2001;1403-1414
58. Weiss T., Veh R.W., Heinemann U. Dopamine depresses cholinergic oscillatory network activity in rat hippocampus. Eur J Neurosci. 18(9):2003;2573
59. 2 receptors necessary for the expression of dopamine-mediated behaviors? Pharm Biochem Behav. 30:1988;189-193
60. Williams S.M., Goldman-Rakic P.S. Characterization of the dopaminergic innervation of the primate frontal cortex using a dopamine-specific antibody. Cereb Cortex. 3:1993;199-222
61. Wright J.W., Miller-Wing A.V., Shaffer M.J., Higginson C., Wright D.E., Hanesworth J.M., Harding J.W. Angiotensin II (3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory. Brain Res Bull. 32:1993;497-502
62. Wright J.W., Reichert J.R., Davis C.h.J., Harding J.W. Neural plasticity and the brain renin-angiotensin system. Neurosci Biobehav Rev. 26:2002;529-652
63. Wright J.W., Stubley L., Pederson E.S., Kramar E.A., Hanesworth J.M., Harding J.W. Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci. 19:1999;3952-3961
64. Yen S.H., Pan J.T. Atrial natriuretic peptide negatively modulates the stimulatory effects of angiotensin II on tuberoinfundibular dopaminergic neuronal activity. Neuroendocrinology. 66:1997;313-320